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Abstract
Background—Pulmonary arterial hypertension (PAH) is a rare disease with an emerging genetic 
basis. Heterozygous mutations in the gene encoding the bone morphogenetic protein receptor 
type 2 (BMPR2) are the commonest genetic cause of PAH, whereas biallelic mutations in the 
eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) are described in 
pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis (PVOD/PCH).
Here, we determined the frequency of these mutations and define the genotype-phenotype 
characteristics in a large cohort of patients diagnosed clinically with PAH.
Methods—Whole genome sequencing was performed on DNA from patients with idiopathic and 
heritable PAH, as well as PVOD/PCH recruited to the NIHR BioResource - Rare Diseases
Study. Heterozygous variants in BMPR2 and biallelic EIF2AK4 variants with a minor allele 
frequency of < 1:10,000 in control data sets and predicted to be deleterious (by CADD,
PolyPhen-2 and SIFT predictions) were identified as potentially causal. Phenotype data from the 
time of diagnosis were also captured.
Results—Eight hundred and sixty-four patients with idiopathic or heritable PAH and 16 with 
PVOD/PCH were recruited. Mutations in BMPR2 were identified in 130 patients (14.8%). 
Biallelic mutations in EIF2AK4 were identified in 5 patients with a clinical diagnosis of 
PVOD/PCH. Furthermore, 9 patients with a clinical diagnosis of PAH carried biallelic EIF2AK4
mutations. These patients had a reduced transfer coefficient for carbon monoxide (KCO: 33
[IQR: 30 - 35] % predicted) and younger age at diagnosis (29 [23 - 38] years) as well as more 
interlobular septal thickening and mediastinal lymphadenopathy on computed tomography of the 
chest, compared to PAH patients without EIF2AK4 mutations. However, radiological assessment 
alone could not accurately identify biallelic EIF2AK4 mutation carriers. PAH patients with 
biallelic EIF2AK4 mutations had a shorter survival. 
Conclusions—Biallelic EIF2AK4 mutations are found in patients classified clinically as 
idiopathic and heritable PAH. These patients cannot be identified reliably by CT, but a low KCO
and a young age of diagnosis suggests the underlying molecular diagnosis. Genetic testing can
identify these misclassified patients, allowing appropriate management and early referral for lung 
transplantation. 
Key Words: genetics, human; pulmonary hypertension; prognosis; EIF2AK4, pulmonary veno-
occlusive disease
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Clinical Perspective 
What is new? 
? 1% of patients with a clinical diagnosis of PAH carry biallelic EIF2AK4 mutations.  
? Patients diagnosed clinically with PAH who had a KCO < 50% predicted and age of 
diagnosis < 50 years were more likely to carry biallelic EIF2AK4 mutations. The 
diagnostic yield for genetic testing in this group was 53%. 
? Radiological assessment was unable to distinguish reliably between these patients and 
idiopathic PAH patients.
? Histology from these patients may show predominately pulmonary arteriopathy, with 
subtle involvement of the pulmonary veins and capillaries.
? PAH patients with biallelic EIF2AK4 mutations had a worse prognosis compared to other 
PAH patients.
What are the clinical implications?
? Younger patients diagnosed with idiopathic PAH, but with a low KCO, have a high 
frequency of biallelic EIF2AK4 mutations.
? Such patients should be reclassified as pulmonary veno-occlusive disease/pulmonary 
capillary haemangiomatosis (PVOD/PCH).
? Similar to patients with PVOD/PCH these patients have a poor prognosis compared to 
other PAH patients. 
? The spectrum of radiological and histological changes associated with biallelic EIF2AK4
mutations is wider than previously assumed. The presence of only subtle or infrequent 
features associated with PVOD may lead to misclassification of these patients as PAH.
? Genetic testing allows early identification of these patients, facilitating appropriate 
management. 
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Pulmonary arterial hypertension (PAH) is a heterogeneous and rare disorder that can be 
classified into idiopathic and heritable forms, associated with an underlying condition, such as 
connective tissue disease or congenital heart disease, or related to specific drugs and toxins 1, 2.
In addition, pulmonary veno-occlusive disease (PVOD) and pulmonary capillary 
haemangiomatosis (PCH) are even rarer forms of pulmonary hypertension that are grouped 
together with PAH under the current classification system 2.
Clinical features described in patients with PVOD/PCH include a low transfer coefficient 
for carbon monoxide (KCO) and oxygen desaturation on exertion, as well as the presence of 
centrilobular ground glass opacification, interlobular septal thickening and mediastinal 
lymphadenopathy on high resolution computed tomography (HRCT) of the lung parenchyma 3, 4.
However, these clinical and radiological features have also been reported in idiopathic PAH 5-7.
Consequently, the clinical distinction between PVOD/PCH and idiopathic PAH can be
challenging. It has been estimated that 10% of patients with PVOD/PCH are misdiagnosed as 
idiopathic PAH 8, 9. The diagnosis of PVOD/PCH is often only confirmed post mortem, or from 
explanted lungs, by histology.  
The histological features of PVOD/PCH typically include pulmonary venous obstructions 
and pulmonary capillary proliferation, although the distribution of these changes within the lung 
can be heterogeneous 10, 11. Pulmonary artery smooth muscle hypertrophy and intimal 
hyperplasia, similar to the changes observed in other forms of PAH, may also be present.
Furthermore, pulmonary venous changes have been reported in cases of idiopathic PAH,
scleroderma-associated PAH and those with BMPR2 mutations, to varying extents 12, 13. 
 A major advance in the molecular diagnosis of PVOD/PCH was the finding of biallelic 
mutations in the gene encoding the eukaryotic translation initiation factor 2 alpha kinase 4 
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(EIF2AK4) in both familial (100%) and sporadic (20-25%) cases of PVOD/PCH 14, 15. EIF2AK4 
is an activator of the integrated stress response (ISR) pathway, and responds to environmental 
stresses, including amino acid deprivation, by phosphorylating the alpha subunit of eukaryotic 
translation initiation factor 2 11, 16, 17. These discoveries suggest that EIF2AK4 mutations are 
specific to PVOD/PCH and that finding biallelic EIF2AK4 mutations in a patient with pulmonary 
hypertension would be diagnostic of PVOD/PCH. Patients with PVOD/PCH have a poor 
prognosis and risk fatal pulmonary oedema with the use of pulmonary artery vasodilator 
therapies 4, 18-20. Consequently, early and accurate diagnosis is vital to guide clinical 
management. 
 Heterozygous mutations in the gene encoding the bone morphogenetic protein type 2 
receptor (BMPR2) are the most common genetic cause of PAH. They are found in approximately 
17% of individuals with idiopathic PAH and 82% with a family history of the disease 21.
However, mutations in BMPR2 have also been reported in patients with histologically proven 
PVOD 4, 22-24. Thus, there remains considerable uncertainty to what extent the finding of 
EIF2AK4 or BMPR2 mutations reliably predict the clinical phenotype and response to therapy in 
a population of patients with PAH. 
Here we report the genetic and phenotypic characteristics of patients assessed for BMPR2
and EIF2AK4 mutations, through whole genome sequencing, within a large cohort (n=880) of 
PAH patients recruited to the National Institute of Health Research (NIHR) BioResource – Rare 
Diseases (BRIDGE) Study (Supplementary Table 1). The frequency of mutations in other 
previously reported genes associated with PAH will be reported in a future publication. In this 
study, we identified and characterised patients with a clinical and radiological diagnosis of 
idiopathic PAH who were found to possess biallelic EIF2AK4 mutations. These patients had a
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low KCO and were diagnosed at a younger age compared with idiopathic PAH patients without 
mutations in these genes. We show that, in common with patients diagnosed clinically with
PVOD/PCH, PAH patients with biallelic EIF2AK4 mutations have a shorter survival. We 
conclude that clinical assessment alone is inadequate for the accurate diagnosis of PVOD/PCH. 
Clinical genetic testing in younger patients presenting clinically with PAH but with a low KCO,
will allow appropriate classification, leading to better risk stratification and management of these 
patients.
Methods
Ethical approval and consent 
UK patients (621 [70.6%]) were recruited prospectively to the BRIDGE Study and provided 
written informed consent for genetic analysis and the capture of clinical data (NIHR 
BioResource - Rare Diseases Study 13/EE/0325). Additionally, the study included patients 
recruited retrospectively from non-UK centres (191 [21.7%]), and deceased UK patients (68 
[7.7%]), if they had signed local tissue bank consent forms allowing genetic sequencing. 
Explanted lung tissue from an individual undergoing lung transplantation for end stage PAH was 
collected under Papworth Hospital Research Tissue Bank ethics (08/H0304/56). 
Recruitment and patients 
The BRIDGE Study is a prospective study recruiting both prevalent and incident patients with 
selected rare diseases. Recruitment to the BRIDGE PAH Study started in January 2013 and the 
last patient included in this analysis was recruited on 15/06/2016. Patients with idiopathic PAH, 
heritable PAH, PVOD and PCH, diagnosed according to international guidelines at specialist 
pulmonary hypertension centres in the United Kingdom, Netherlands and France, were recruited
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(Figure 1 and Supplementary Table 2) 2. This included 14 patients with confirmed mutations in 
BMPR2.  
 Throughout the manuscript, we classify patients recruited to the study as idiopathic PAH 
or familial PAH based on the absence or presence of a family history of the disease. The term 
heritable PAH does not distinguish between sporadic PAH patients with a mutation, and patients 
with a mutation where there is a family history. Therefore, the term “heritable PAH” is only used 
when referring to previous publications and guidelines. 
 Patients with other rare diseases and their unaffected relatives recruited to the BRIDGE 
Study (Supplementary Table 3) acted as non-PAH controls for the genetic analysis.  
Whole genome sequencing and variant calling 
Next generation sequencing using 100-150 base pair paired-end sequencing was performed on 
DNA libraries created from genomic DNA using Illumina HiSeq 2500 and HiSeq X (Illumina 
Inc, San Diego, USA). 
 Reads were aligned against the Genome Reference Consortium human genome (build 37) 
(GRCh37) and variants were called using the Issac Aligner and Variant Caller respectively 
(version 2, Illumina Inc.). Variants in BMPR2 and EIF2AK4 were extracted and annotated using 
Ensembl’s Variant Effect Predictor (VEP) v84 25. Deletions (resulting in the loss of more than 
50bp) were identified by applying Isaac Copy Number Variant Caller (Canvas, Illumina) and 
Isaac Structural Variant Caller (Manta, Illumina). Further information is provided in the 
supplemental materials.
Likely causal variants were identified based on minor allele frequency (MAF) and 
predicted deleteriousness. Variants were considered further if they had a MAF of less than 1 in 
10,000 in unrelated non-PAH BRIDGE controls and the ExAC database 26. The rare variants that 
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passed the MAF filtering were then assessed for deleteriousness. Variants were considered 
pathogenic based on a combined annotation dependent depletion (CADD) score of 15 or higher 
and PolyPhen-2 or SIFT predictions not classified as “benign” or “tolerated” respectively 27-29. 
Over-representation analyses
For comparison of variant frequencies between disease and control groups only variants from 
unrelated individuals were used. The PRIMUS software package was used to identify non-
related individuals amongst both non-PAH BRIDGE controls and PAH patients 30. The number 
of unrelated control subjects was maximised by including either patients with other rare diseases 
or their unaffected relatives. The frequency of rare and predicted deleterious heterozygous 
EIF2AK4 variants in PAH index cases was also compared to publically available information in 
the ExAC database (http://exac.broadinstitute.org) 26. This analysis provides the maximum 
estimate of the frequency of heterozygous EIF2AK4 variants in the ExAC database as variants in 
ExAC were assumed not to be in a compound heterozygous state.  
Phenotypic data capture and CT assessment
Paper and electronic patient records of PAH patients were reviewed to capture demographic and 
phenotypic variables from the time of diagnosis and follow up. Survival data for UK patients 
were obtained from recruiting centres through the NHS National Spine and local databases. 
Anonymised information was captured securely online using the free OpenClinica? software, 
adapted for data capture specific to PAH. 
CT images of the chest, where available, were reviewed independently by 2 
cardiothoracic radiologists (AS and NS), with specialist imaging experience in pulmonary 
hypertension, blinded to the underlying diagnoses using a customised proforma. Further 
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information is provided in the supplemental materials, Supplementary Table 4 and 
Supplementary Table 5.
Statistical analysis 
Statistical analysis was performed in R (www.r-project.org). Further information is provided in 
the supplemental materials.
Semi-parametric Cox-proportional hazard models were used to assess survival between 
groups using the “survival” package in R. Time from diagnosis to both death and death or 
transplantation was assessed. Age at diagnosis and gender were used as covariates in the models.
To avoid immortal time bias arising from the inclusion of retrospectively recruited patients and 
prevalent patients, a sensitivity analysis was conducted. In this analysis only prospectively 
recruited patients from the UK were included and patients entered the risk set only from the time 
they consented to the study. Further information is provided in the supplemental materials.
Results
Study patients  
Whole genome sequencing was performed on 932 patients recruited to the NIHR BRIDGE PAH 
Study and 7134 non-PAH control subjects recruited to other NIHR BRIDGE Study cohorts. 
Fifty-two patients were excluded from further analysis because they did not have a clinical 
diagnosis of idiopathic PAH, heritable PAH, PVOD or PCH (Figure 1). The remaining 880
patients (of which 872 were defined as unrelated index cases) consisted of 16 patients (1.8%) 
with a clinical diagnosis of PVOD/PCH, 56 (6.4%) with PAH and a family history of the disease 
(referred to as familial PAH) and 808 (91.8%) with idiopathic PAH and no known family 
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history. One of the 16 patients with a clinical diagnosis of PVOD/PCH had an affected sister,
whereas the remainder had the sporadic form of the disease. 
BMPR2 mutations in the PAH cohort
Rare and predicted deleterious BMPR2 mutations (single nucleotide variants, indels and larger 
deletions) were found in 41 patients (73.2%) with familial PAH and 89 patients (11.0%) with 
idiopathic PAH. No BMPR2 mutations were found in patients with a clinical diagnosis of 
PVOD/PCH.
Rare and predicted deleterious EIF2AK4 variants in the PAH cohort
Sixty-nine rare and predicted deleterious EIF2AK4 single nucleotide variants and indels were 
present in the NIHR BRIDGE Study. No large deletions were found that affected the EIF2AK4
gene locus. The variants are summarised in Supplementary Table 6. Five of the 16 patients 
(31.3%) with clinically diagnosed PVOD/PCH carried biallelic EIF2AK4 mutations (2 
homozygotes and 3 compound heterozygotes).  
Twenty-five EIF2AK4 variants were also found in 19 patients (2.2%) diagnosed clinically 
with PAH, in whom there was no clinical diagnosis of PVOD/PCH (5 homozygotes, 4 compound 
heterozygotes and 10 heterozygotes; Supplementary Table 7). One of these patients with a
homozygous EIF2AK4 mutation (c.3097C>T creating a premature stop codon) had a sister who 
had died of PAH. There was no reported family history of PVOD/PCH.  
The remaining rare EIF2AK4 variants were found in a heterozygous state in 36 control 
subjects (0.5%). Four of these variants appeared in more than 1 non-PAH control subject and
none were shared with PAH patients. 
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Over-representation of rare heterozygous EIF2AK4 variants in idiopathic PAH patients 
compared to control subjects
The proportion of patients with a clinical diagnosis of idiopathic PAH carrying heterozygous rare
EIF2AK4 variants (1.2%) was significantly greater than the non-PAH control subjects (0.5%; p = 
0.030). A similar over-representation in idiopathic PAH patients was observed when compared 
to allele frequencies in the ExAC database (0.6%; p = 0.042). Two idiopathic PAH patients with 
heterozygous rare EIF2AK4 variants also carried a rare and predicted deleterious BMPR2
mutation.
Phenotype of patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations  
Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations presented at a 
younger age (median [IQR]: 29 [23 - 38] years) compared to patients without these variants (51 
[37 - 65] years; p = 0.024) (Table 1). Mean pulmonary artery pressure, cardiac output and 
pulmonary vascular resistance were not significantly different between PAH patients with
biallelic EIF2AK4 mutations and the other groups. As previously reported, haemodynamic 
variables were significantly more severe in patients with BMPR2 mutations compared to those 
without any mutations in these genes.  
 The PAH patients with biallelic EIF2AK4 mutations exhibited a reduced KCO (33 [30 - 
35] % predicted) compared to BMPR2 mutation carriers (81 [73 - 92] % predicted, p < 0.001)
and PAH patients with no identified mutation (71 [51 - 85] % predicted, p = 0.001). PAH 
patients with biallelic EIF2AK4 mutations had no obstructive or restrictive deficit on spirometry. 
These differences remained after exclusion of patients with abnormal spirometry in the other 
groups (FEV1 < 80% or FVC < 80%) (Supplementary Table 8).  
 by guest on O
ctober 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.028351
12
Digital clubbing was over-represented amongst patients with biallelic EIF2AK4
mutations diagnosed clinically with PAH (42%; p=0.002).  Eleven percent of patients with a 
clinical diagnosis of PVOD were clubbed.
 Only one patient with a heterozygous rare and predicted deleterious EIF2AK4 variant 
(c.2516T>C) had a reduced KCO (54% predicted) with normal spirometry (FEV1 102% 
predicted, FVC 98% predicted and TLC 100% predicted). Although, there was mild paraseptal 
emphysema on thoracic CT (< 5% of the lung parenchyma affected). This patient, a 44-year-old 
Caucasian male diagnosed with idiopathic PAH, also carried a rare and deleterious BMPR2
splice acceptor mutation (c.853-2A>G).  
 We questioned whether KCO was a predictor of biallelic EIF2AK4 mutations in the 
wider cohort. However, amongst PAH patients with no mutations and normal spirometry 
(n=255), a reduced KCO (< 50% predicted) was present in 65 patients (25.5%). In these patients 
with a reduced KCO and preserved spirometry, 90.8% were aged over 50 years at diagnosis and 
69.2% had a history of coronary artery disease, left ventricular dysfunction or cardiovascular risk 
factors (diabetes mellitus, systemic hypertension or hyperlipidaemia).  
 Given the high prevalence of a low KCO with preserved spirometry in the wider cohort, 
we restricted an analysis to patients under the age of 50 years, who at the time of diagnosis had
normal spirometry (n=164). Even, in this group a significant proportion (15, 9.1%) had a KCO < 
50% predicted (Figure 2). Eight of these 15 patients carried biallelic EIF2AK4 mutations. One
patient with biallelic EIF2AK4 mutations was aged 70 years at diagnosis and subsequently did 
not meet this cut-off.  
Amongst patients with normal spirometry, the presence of a KCO < 50% predicted and 
age at diagnosis < 50 years had a high sensitivity (0.889) and specificity (0.977) for identifying 
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patients who carry biallelic EIF2AK4 mutations, the positive predictive value was low (0.533).
Nevertheless, in terms of the diagnostic yield, while genetic testing for biallelic EIF2AK4
mutations in the entire cohort of patients diagnosed clinically with PAH yielded a 1% detection 
rate, the presence of biallelic EIF2AK4 mutations in PAH patients with a KCO < 50% with 
normal spirometry and aged under 50 at diagnosis was 53%.  
CT features of EIF2AK4 mutation carriers
Centrilobular ground glass opacification extent, mediastinal lymphadenopathy and interlobular 
septal thickening are considered suggestive of PVOD/PCH. However, we found subtle or gross 
centrilobular ground glass opacification in 38% of patients diagnosed clinically with PAH and 
carrying no mutations (n=21) and 67% of PAH patients with BMPR2 mutations (n=21). This was 
not significantly different compared to patients with a clinical diagnosis of PAH and biallelic 
EIF2AK4 mutations (86%, n=7) and patients with a clinical diagnosis of PVOD (50%, n=14). 
Gross interlobular septal thickening and mediastinal lymphadenopathy was significantly more 
frequent amongst patients with PAH and biallelic EIF2AK4 mutations (29% and 57% 
respectively) and those with PVOD (64% and 79%) compared to patients with PAH and no 
mutation (5% and 0%) or BMPR2 mutations (5% and 10%). A radiological suspicion of 
PVOD/PCH was raised in 71% of those with PVOD, 57% of patients with a clinical diagnosis of 
PAH and biallelic EIF2AK4 mutations, 14% of PAH patients with no mutation, and 5% of those 
with BMPR2 mutations (Table 2).  
A further CT analysis comparing patients with biallelic EIF2AK4 mutations (with a 
clinical diagnosis of PVOD/PCH or PAH; n=11) and those with a clinical diagnosis of PVOD 
but not carrying biallelic EIF2AK4 mutations (n=10) was made (Supplementary Table 9). 
Patients with biallelic EIF2AK4 mutations were younger at diagnosis (27 [IQR: 23 - 34] years) 
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compared to those with PVOD and no EIF2AK4 mutations (68 [64 - 72] years, p=0.001). The 
patients with biallelic EIF2AK4 mutations also had a lower KCO (32 [29 – 33] % predicted) 
compared to patients with PVOD and no EIF2AK4 mutations (41.4 [37 – 54] % predicted, 
p=0.013). Centrilobular ground glass opacification appeared more extensive in those with 
biallelic EIF2AK4 mutations (82%) compared to those without a mutation (10%; p=0.012). 
However, pleural effusions were more common amongst those without a mutation (40%) 
compared to patients with biallelic EIF2AK4 mutations (0%, p=0.035). This may suggest that 
patients with biallelic EIF2AK4 mutations have a distinct radiological phenotype compared to 
patients with PVOD and no biallelic EIF2AK4 mutations.
Response to pulmonary artery vasodilator therapies 
The response to pulmonary artery vasodilator therapies at 1 and 3 years was assessed for patients 
with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations as well as the other PAH 
patients included in the CT analysis.  Patients with a clinical diagnosis of PAH and biallelic 
EIF2AK4 mutations did not improve their functional class at either 1 year or 3 years post 
diagnosis unlike the other PAH groups (Supplementary Table 10). 
Histological features of biallelic EIF2AK4 mutation carrier
The explanted lungs of one patient diagnosed with idiopathic PAH but found to have a
homozygous EIF2AK4 missense mutation (c.1795G>C, p.G599R) were assessed. The 
predominant histological feature was pulmonary arterial vasculopathy. The pulmonary arteries
predominantly showed concentric and eccentric intimal fibrosis. No plexiform lesions were 
observed. Although infrequent, there was some fibrosis of the septal veins and venules, some of 
which were nearly completely occluded. Although there was evidence of capillary congestion, no 
capillary hemangiomatosis was observed (Figure 3). The missense variant carried by this patient 
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was not reported in the ExAC database, occurs in a conserved area of the genome (GERP score 
5.5) and was predicted to be deleterious (CADD score 32, PolyPhen-2 prediction of “probably 
damaging [1]”, SIFT prediction of “deleterious [0]”). The same homozygous mutation was also 
found in a second unrelated patient with a clinical diagnosis of idiopathic PAH.
Impact of genotype on survival 
Eight hundred and fifty-eight patients were included in the Cox proportional hazards model 
(Supplementary Table 11, Supplemental Figure 1). Patients diagnosed clinically as PAH with 
biallelic EIF2AK4 mutations had a shorter survival time from diagnosis compared to the BMPR2
mutation carriers (p < 0.001) and those without any variants in PAH associated genes (p < 
0.001). Age (p < 0.001) and gender (p = 0.001) also had a significant effect on survival, with 
male sex and an older age at diagnosis associated with shorter survival in the model. Similar 
results were obtained when assessing the time to death or transplantation (Supplementary Tables 
12). In the sensitivity analysis, including only prospectively recruited UK patients, only 2 events 
occurred in the biallelic EIF2AK4 group. Thus no significant difference was observed in 
mortality between patients diagnosed clinically as PAH with biallelic EIF2AK4 mutations and 
patients with BMPR2 mutations (p = 0.215), or patients without any variants in PAH associated 
genes (p = 0.282; Supplementary Table 13).  
Discussion
This is the first study to analyse the frequency of EIF2AK4 rare variation in a large cohort of 
PAH patients and make detailed phenotypic and radiological assessments. Previously the 
presence of biallelic EIF2AK4 mutations were reported in patients with a clear clinical diagnosis 
of PVOD/PCH as well as a large kindred and a single family with a possible diagnosis of PAH 20, 
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31, 32. As expected, we identified a high frequency of biallelic EIF2AK4 mutations in patients 
with a clear clinical presentation of PVOD/PCH. However, we also found biallelic EIF2AK4
mutations in patients with a clinical diagnosis of PAH.
The discovery of biallelic EIF2AK4 mutations in PVOD/PCH raised the possibility of 
rapid molecular diagnosis in the majority of patients with familial, and up to 25% of patients 
with sporadic PVOD/PCH 14, 15. In the present study, the presence of biallelic EIF2AK4
mutations was associated with a poor prognosis, even in patients who have a clinical diagnosis of 
PAH, and who did not develop pulmonary oedema in response to pulmonary artery vasodilator 
therapies. Therefore, early identification of these patients through genetic testing may prompt 
early referral for lung transplantation similar to patients with clinically diagnosed PVOD/PCH 18.  
The presence of biallelic EIF2AK4 mutations in patients with a clinical diagnosis of PAH
raises the question whether EIF2AK4 mutations can cause classical idiopathic PAH, or whether 
there are cases of PVOD/PCH caused by EIF2AK4 mutations that are wrongly classified even by 
expert centres. We further show that phenotypic, radiological and histological assessments can 
be difficult to interpret. The presence of subtle or infrequent features may lead to an incorrect 
diagnosis of PAH in patients with biallelic EIF2AK4 mutations. This study suggests that patients 
with pathogenic biallelic EIF2AK4 mutations may present with a spectrum of phenotypic, 
radiological and histological features that can overlap with PAH.
PAH patients with biallelic EIF2AK4 mutations demonstrated a reduced KCO despite 
normal spirometry, which is characteristic of patients with PVOD/PCH. The reduced KCO likely 
reflects widespread reduction in alveolar gas exchange due to endothelial proliferation and 
patchy thickening of the blood gas barrier by the process of capillary haemangiomatosis. 
Ultrastructural thickening of the capillary basement membrane may also play a role 33. In 
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keeping with previous reports in PVOD/PCH we also show that PAH patients with biallelic 
mutations in EIF2AK4 are younger at diagnosis than patients with either BMPR2 mutations or no 
known mutation 14, 20. However, the presence of these characteristic features has a low positive 
predictive value for the identification of patients with biallelic EIF2AK4 mutations.  
 In contrast to previous descriptions of patients with PVOD, none of the patients with 
clinically diagnosed PAH and biallelic EIF2AK4 mutations developed pulmonary oedema in 
response to pulmonary artery vasodilator therapies. For example, intravenous prostanoids were 
used in 50% of these patients. In classical PVOD patients, pulmonary oedema with intravenous 
prostanoids has been reported in up to 44% of patients after a median treatment duration of just 9 
days 4. Presumably the extent and severity of the pulmonary venous involvement in these 
patients might underlie the differing responses to prostanoids. 
It is generally considered that HRCT imaging is a useful non-invasive test to assist in the 
diagnosis of suspected PVOD/PCH 11. Although there was an increased prevalence of 
mediastinal lymphadenopathy and interlobular septal thickening in PAH patients with biallelic 
EIF2AK4 mutations, we found that radiological features at the time of diagnosis could not 
accurately determine the underlying genotype 6. The differing radiological features of all patients 
with biallelic EIF2AK4 mutations compared with PVOD cases without mutations is of interest.
This may reflect differences between the younger onset genetic cases of PVOD, compared with 
the predominantly older group of patients without EIF2AK4 mutations in whom other non-
genetic factors, such as exposure to inorganic solvents, may play an important role 34. 
Histological examination (usually post mortem or from explanted lungs) is often 
considered essential for diagnostic confirmation of PVOD/PCH but may be confounded by the 
heterogeneous nature of vascular pathology 35. Surgical biopsy of the lung in patients with severe 
 by guest on O
ctober 11, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.028351
18
PAH is contraindicated and a limitation of this study is that lung tissue from only one patient 
with biallelic EIF2AK4 mutations was available for analysis. This patient had a rare and 
predicted deleterious homozygous missense mutation in EIF2AK4. The predominant feature on 
assessment of the explanted lung tissue was of pulmonary arteriopathy, as usually seen in PAH. 
Although only infrequent, fibrosis of the septal venules and the possible presence of 
siderophages in the alveolar space were observed. These features are found in patients with 
PVOD/PCH. This case supports the hypothesis that patients with biallelic EIF2AK4 mutations 
may present with a spectrum of venous and arterial involvement. 
There are increasing reports of phenotypic, radiological and histological similarities 
between PAH and PVOD/PCH 6, 12, 13. Tenorio et al. reported a homozygous missense mutation 
in EIF2AK4 in a large kindred of Iberian Romani with apparent heritable PAH 31. This kindred is 
likely to have PVOD/PCH as these diagnoses were not confirmed histologically and PVOD was 
suspected in half the patients. More recently, Best et al. also report two sisters with apparent 
heritable PAH carrying biallelic EIF2AK4 mutations 32. These patients also had a reduced KCO 
but had not had HRCT assessment of their lung parenchyma which may have altered their 
clinical diagnosis. Taken together, these previous reports are compatible with the findings in this 
larger cohort, that patients with a clinical presentation of idiopathic or heritable PAH may in fact 
have underlying PVOD/PCH as determined by genetic analysis. 
 A strength of this study is the centralised reporting of radiographic features. However, the 
data collection was retrospective and incomplete in some cases. Assessing rare diseases, such as 
PAH and PVOD/PCH, with a prospective study recruiting incident cases would take a 
prohibitively long time. This is especially true when assessing survival and response to therapy. 
In this study including prevalent and retrospectively recruited patients, we demonstrated a worse 
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prognosis in patients with a clinical diagnosis of PAH and biallelic EIF2AK4. However, the 
inclusion of prevalent and retrospectively recruited patients can introduce bias such as immortal 
time bias, when there are long periods between diagnosis and enrolment in the study. The effect 
of immortal time bias and other confouders such as the inclusion of prevalent and incident cases 
can be difficult to predict. In all groups there are likely to be patients who died prior to study 
enrolment, and thus would not feature in any analysis. When we attempted to eliminate these 
sources of bias in a sensitivity analysis restricted to prospectively recruited patients from the UK, 
the study did not have sufficient power to show a difference in survival between different 
genotypes. Further studies of survival and response to therapy will be needed to definitively 
show whether “misclassified” PAH patients with biallelic EIF2AK4 mutations have a similarly 
poor prognosis as classical PVOD patients with these mutations.
The genetic architecture of idiopathic and heritable PAH remains to be fully elucidated.
Ongoing analysis of whole genome sequence data in our cohort is likely to reveal novel rare 
variation underlying this condition. Mutations in BMPR2 account for approximately 17% of 
idiopathic PAH patients and other known PAH genes account for approximately 1-2% of all 
cases 21, 36. In the present study BMPR2 mutations were found in 11% of patients without a 
family history of PAH. It is worth noting that patients with the sporadic form of the disease with 
no reported family history represent a higher burden of BMPR2 mutations (n=89) compared to 
those with a family history (n=49). This has important implications for clinical genetic testing in 
patients with sporadic as well as familial disease.
 In previous studies mutations in both EIF2AK4 alleles are required to cause PVOD and 
PCH 14, 15. In autosomal recessive disorders, it is unusual for the heterozygous state to manifest 
the disease phenotype and thus heterozygous EIF2AK4 variants would not be expected to be 
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pathogenic. In this study, we found a significant over-representation of heterozygous rare and 
predicted deleterious EIF2AK4 variants in PAH compared to control subjects and report 2 
patients with rare variants in both BMPR2 and EIF2AK4. Recently, the possibility that 
heterozygous EIF2AK4 variants influence the penetrance of BMPR2 mutations has been raised in 
a single family with PAH 37. Further studies are required to determine whether heterozygous 
EIF2AK4 variants contribute to aetiology in PAH. 
In summary, we demonstrate that biallelic EIF2AK4 mutations are found in patients 
diagnosed clinically with idiopathic and familial PAH. These patients may have subtle features 
suggestive of PVOD/PCH on close inspection and are likely to have underlying PVOD/PCH.
The spectrum of phenotypic, radiological and histological features found in patients with 
biallelic EIF2AK4 mutations made by current clinical assessments is wider and less clear cut 
than previously recognised.  This may lead to misclassification of patients as PAH rather than 
PVOD and hinders accurate risk stratification. Ascertaining the EIF2AK4 mutation status of 
patients through clinical genetic testing provides additional information to aid risk stratification 
and guide management. In a young patient presenting with apparent PAH, the presence of a low 
KCO with normal spirometry strongly suggests the presence of underlying biallelic EIF2AK4
mutations. Patients with an apparent clinical diagnosis of PAH and biallelic EIF2AK4 mutations 
have a worse prognosis compared to patients with BMPR2 mutations and those without these 
mutations. Clinical genetic testing should aid identification of this high-risk group and facilitate 
early referral for lung transplantation and appropriate management.  
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Table 1. Phenotypic summary of EIF2AK4 variant carriers. Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations 
are younger at diagnosis and have a significantly reduced KCO compared to other groups. 
PAH patients with 
BMPR2 mutations *
PAH patients with no 
mutations in PAH 
associated genes
PAH patients with 
EIF2AK4
heterozygous 
variants
PAH patients with 
biallelic EIF2AK4
mutations
PVOD/PCH 
patients p
n 130 704 8 9 16
Age (years) 39 [31 - 52] 51 [37 - 65] 49 [36 - 67] 29 [23 - 38] 57 [41 - 69] <0.001
Gender (n female [%]) 85 [65.4%] 494 [70.2%] 7 [87.5%] 4 [44.4%] 9 [56.2%] 0.18
Ethnicity (n white Caucasian [%]) 108 [83.1%] 551 [78.5%] 5 [62.5%] 2 [22.2%] 13 [81.2%] 0.002
Digital clubbing
(n [%]) 6 [9.7%] 10 [3.4%] 0 [0%] 3 [42.9%] 1 [11.1%] 0.002
BMI 28 [24 - 33] 28 [24 - 33] 26 [23 - 28] 24 [20 - 27] 27 [24 - 31] 0.216
mPAP (mmHg) 57 [51 - 69] 52 [44 - 61] 44 [42 - 52] 52 [46 - 65] 48 [40 - 58] <0.001
CO (L/min) 3 [3 - 4] 4 [3 - 5] 3 [3 - 5] 5 [3 - 6] 4 [3 - 4] <0.001
PVR (WU) 15 [11 - 20] 10 [7 - 14] 9 [6 - 10] 9 [8 - 13] 10 [9 - 12] <0.001
Vasoresponders (n [%]) 0 [0%] 28 [17.5%] 0 [0%] 0 [0%] 0 [0%] 0.011
FEV1 (%pred) 90 [78 - 99] 84 [72 - 95] 83 [71 - 94] 94 [85 - 100] 85 [70 - 95] 0.031
FVC (%pred) 97 [86 - 109] 95 [82 - 106] 96 [75 - 98] 100 [86 - 119] 97 [81 - 103] 0.310
KCO (%pred) 81 [73 - 92] 71 [51 - 85] 81 [72 - 95] 33 [30 - 35] 37 [32 - 47] <0.001
Resting SAO2 (%) 96 [94 - 97] 96 [93 - 97] 98 [98 - 98] 91 [90 - 94] 94 [91 - 95] 0.010
SAO2 post walk test (%) 94 [90 - 97] 92 [85 - 96] 94 [84 - 96] 78 [75 - 82] 88 [85 - 89] <0.001
BMI - body mass index, mPAP - mean pulmonary artery pressure, PVR - pulmonary vascular resistance, FEV1 - forced expiratory volume in 1 second, FVC - 
forced vital capacity, KCO - transfer coefficient for carbon monoxide. * Also includes the 2 patients with a heterozygous EIF2AK4 variant and a BMPR2 
variant. Data presented as median [IQR] unless indicated. Percentages were calculated using the number of patients for whom data were available as the 
denominator.
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Table 2. Radiological features and consensus radiological diagnosis of PAH patients in the CT substudy 
Group PAH patients with BMPR2 mutations
PAH patients with 
no mutations in the 
previously reported 
PAH genes
PAH patients with 
heterozygous 
EIF2AK4 variants
PAH patients with 
biallelic EIF2AK4
mutations
PVOD p 
n 21 21 4 7 14
Centrilobular ground glass 
opacification density
None 7 [33.3%] 13 [61.9%] 2 [50.0%] 1 [14.3%] 7 [50.0%]
0.122Subtle 12 [57.1%] 5 [23.8%] 0 [0.0%] 2 [28.6%] 3 [21.4%]
Present 2 [9.5%] 3 [14.3%] 2 [50.0%] 4 [57.1%] 4 [28.6%]
Centrilobular ground glass 
opacification extent
None 8 [38.1%] 13 [61.9%] 2 [50.0%] 1 [4.3%] 8 [57.1%]
0.077
<5% 0 [0.0%] 3 [14.3%] 0 [0.0%] 1 [14.3%] 1 [7.1%]
5-25% 2 [9.5%] 0 [0.0%] 1 [25.0%] 2 [28.6%] 1 [7.1%]
25-50% 2 [9.5%] 4 [19.0%] 0 [0.0%] 0 [0.0%] 2 [14.3%]
50-75% 5 [23.8%] 1 [4.8%] 0 [0.0%] 2 [28.6%] 0 [0.0%]
75-100% 4 [19.0%] 0 [0.0%] 1 [25.0%] 1 [14.3%] 2 [14.3%]
Interlobular septal 
thickening
None 17 [81.0%] 18 [85.7%] 4 [100.0%] 5 [71.4%] 4 [28.6%]
0.001Subtle 3 [14.3%] 2 [9.5%] 0 [0.0%] 0 [0.0%] 1 [7.1%]
Present 1 [4.8%] 1 [4.8%] 0 [0.0%] 2 [28.6%] 9 [64.3%]
Mediastinal 
lymphadenopathy
None 19 [90.5%] 21 [100.0%] 4 [100.0%] 3 [42.9%] 3 [21.4%] <0.001Present 2 [9.5%] 0 [0.0%] 0 [0.0%] 4 [57.1%] 11 [78.6%]
Pleural effusion None 17 [81.0%] 21 [100.0%] 3 [75.0%] 7 [100.0%] 10 [71.4%] 0.048Small 4 [19.0%] 0 [0.0%] 1 [25.0%] 9 [0.0%] 4 [28.6%]
Neovascularity None 12 [57.1%] 18 [85.7%] 4 [100.0%] 6 [85.7%] 13 [92.9%] 0.077Present 9 [42.9%] 3 [14.3%] 0 [0.0%] 1 [14.3%] 1 [7.1%]
CT diagnosis
PAH 20 [95.2%] 18 [85.7%] 3 [75.0%] 3 [42.9%] 4 [28.6%]
Possible 
PVOD/PCH 1 [4.8%] 3 [14.3%] 1 [25.0%] 4 [57.1%] 10 [71.4%]
Data presented as n [%].
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Figure Legends
Figure 1. Subjects recruited to the NIHR BioResource – Rare Diseases Study and the 
clinical diagnostic categories of PAH patients included in this study.
Figure 2. The transfer coefficient for carbon monoxide (KCO) is influenced by genotype in 
pulmonary arterial hypertension. Patients with FEV1 < 80 % predicted and FVC < 80 % 
predicted and diagnosed with PAH or PVOD/PCH after 50 years of age excluded from the plot. 
Figure 3. Representative histopathological images from one patient with clinically 
diagnosed idiopathic PAH but found to have a rare (not reported in the ExAC database) 
and predicted deleterious (CADD score 32) homozygous EIF2AK4 missense variant 
(c.1795G>C). The patient was of Pakistani origin and did not have a family history of PAH or 
PVOD. At presentation, he was 22 years old and had a reduced KCO (31% predicted) despite 
preserved spirometry. HRCT of his chest showed subtle but extensive (50-75% involvement) 
ground glass opacification. No interlobular septal thickening or mediastinal lymphadenopathy 
was observed. No suspicion of PVOD/PCH was raised based on radiological appearances. 
Histopathology was reviewed by two independent pathologists each confirming the predominant 
histological pattern to be one of pulmonary arterial vasculopathy. The pulmonary arteries 
showed eccentric and concentric intimal fibrosis and medial hypertrophy (A, B) as well as some 
lesions with features of recanalised thrombus (C). Several concentrically muscularised arterioles 
were also observed (D). No complex plexiform lesions were present. There was patchy 
thickening of the alveolar septa with capillary congestion and pigmented intra-alveolar 
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macrophages similar to PCH (E, F). Venous remodelling was difficult to trace and infrequent, 
but present. Fibrous thickening of the intima in septal veins (G, I) and a micro-vessel (H). 
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SUPPLEMENTAL MATERIAL: 
Phenotypic characterisation of EIF2AK4 mutation carriers in a large cohort of patients 
diagnosed clinically with pulmonary arterial hypertension 
Hadinnapola et al.  
 
Supplemental Methods: 
Whole genome sequencing 
Genomic DNA was extracted from whole blood samples prior to assessment of concentration 
by Qubit, and quality by gel electrophoresis. After fragmentation of DNA into 200bp 
fragments (Covaris E220, Covaris Inc, Woburn, USA) DNA libraries were created using Tru 
SeqDNA LT Prep kit (Illumina Inc, San Diego, USA). The libraries underwent next generation 
sequencing using 100-150 base pair paired-end sequencing using Illumina HiSeq 2500 and 
HiSeq X (Illumina Inc, San Diego, USA). 
 
Variant calling 
Reads were aligned against the Genome Reference Consortium human genome (build 37) 
(GRCh37) and variants were called using the Issac Aligner and Variant Caller respectively 
(version 2, Illumina Inc.). Genebuilds for BMPR2 and EIF2AK4 genes were based on Ensembl 
v75. Variants from these genes were extracted and annotated using Ensembl’s Variant Effect 
Predictor (VEP) v84 1. VEP was also used to annotate data from the Exome Aggregation 
Consortium’s (ExAC) database 2.  
 
Deletions (resulting in the loss of more than 50bp) were identified by applying Isaac copy 
number variant caller (Canvas, Illumina) and Isaac Structural Variant Caller (Manta, Illumina).  
 2 
To be called by both Canvas and Manta deletions required a reciprocal overlap of ≥ 20%. 
Overlapping deletions represented in the Zarrei dataset with a reciprocal overlap of ≥ 50% 
and deletions with a non-PAH BRIDGE control frequency of more than 1 in 1,000 were 
excluded 3. 
  
Analysis of computed tomographic images of the chest  
CT images of the chest, where available, were reviewed independently by 2 cardiothoracic 
radiologists (AS and NS), with specialist imaging experience in pulmonary hypertension, 
blinded to the underlying diagnoses using a customised proforma (Supplemental Table 4). In 
addition to CT scans of patients with EIF2AK4 mutations or with a clinical diagnosis of PVOD 
in the cohort, CT scans of patients from Papworth Hospital and the Royal Hallamshire Hospital 
with normal spirometry (FEV1 > 80% predicted and FVC > 80% predicted) and either BMPR2 
mutations (n=21) or no variants in the known PAH genes (n=21) were analysed (Supplemental 
Table 5). A consensus read was undertaken for individual CT features and a mutually agreed 
overall radiological diagnosis was recorded. 
 
Histology 
The explanted lung tissue of one patient with a clinical diagnosis of idiopathic PAH and biallelic 
EIF2AK4 mutations was available for further analysis. Four micrometre (µm) tissue sections 
were cut from formalin-fixed paraffin wax embedded blocks from the explanted lung tissue. 
Representative sections from each lobe of both lungs were stained with Elastic-Van Gieson 
and Haemotoxylin and Eosin stains. Two expert histopathologists examined the sections 
independently by light microscopy. 
 
 3 
Statistical analysis 
Statistical analysis was performed in R (www.r-project.org). 
 
Differences between groups of categorical variables were assessed using the Fisher Exact test. 
Where one of the variables was an ordinal the Cochran-Armitage test was applied using the 
chisq_test function from the “coin” package 4. Differences in continuous variables were 
assessed using the Mann–Whitney U test (2 comparator groups) and the Kruskal-Wallis test 
(3 or more comparator groups). Post-hoc pairwise comparisons were performed using Dunn’s 
Test for multiple testing.  
 
Semi-parametric Cox-proportional hazards models were used to assess survival between 
groups using the “survival” package in R 5. Survival time from diagnosis to death and diagnosis 
to death or transplantation was assessed. Patients were censored at the date of 
transplantation for the primary survival analysis. Age at diagnosis and gender were used as 
covariates in the models.  
 
The proportional hazards assumptions were tested by assessing Schoenfeld residuals over log 
time 6. The goodness of fit of the model was assessed by plotting the log of cumulative hazard 
of Cox-Snell residuals against the log of time and confirming the simple regression has 0 
intercept and slope of 1 7. 
 
The inclusion of retrospectively recruited and prevalent patients in a survival analysis 
assessing time from diagnosis to death/transplantation can cause immortal time bias. The 
immortal time is the period between diagnosis and enrolment in the study and so patients 
 4 
had to have survived till this point. Patients with worse prognosis diagnosed at a similar time 
may not have survived long enough to enrol in the study. To further explore this potential 
bias, a sensitivity analysis was performed including only on UK patients recruited 
prospectively to the study. In this multivariate Cox-proportional hazards model, the survival 
period was defined as the time period from date of diagnosis to date of death and patients 
only entered the risk set after enrolment into the study (consent date).  
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Supplemental Tables 
Supplemental Table 1.  NIHR BioResource – Rare Diseases Collaboration.  See spreadsheet. 
 
Centre Principle 
Investigator 
Clinicians and research staff 
Freeman Hospital, Newcastle, 
UK 
Paul A Corris Alan Greenhalgh, Debbie Shipley, 
Margaret Day 
Golden Jubilee National 
Hospital, Glasgow, UK 
Andrew 
Peacock 
Colin Church, Val Irvine, Fiona Kennedy 
Great Ormond Street 
Hospital, London, UK 
Shahin 
Moledina 
Victoria Cookson 
Hammersmith Hospital and 
Imperial College, London, UK 
Martin R 
Wilkins 
Simon Gibbs, John Wharton, Sonia Ali, 
Larahmie Masati, Sharon Meehan, Ivy 
Wanjiku, Shokri Othman 
Papworth Hospital, 
Cambridge, UK 
Joanna Pepke-
Zaba 
Mark Toshner, Gary Polwarth 
Royal Brompton Hospital, 
London, UK 
Stephen J Wort Rosa DaCosta, Natalie Dormand, Alice 
Parker 
Royal Free Hospital, London, 
UK 
Gerry Coghlan Yvonne Tan, Dipa Ghedia 
Royal Hallamshire Hospital, 
Sheffield, UK 
David G Kiely Robin Condliffe, Amanda Creaser-Myers, 
Stephen Roney, Sara Walker 
Royal United Hospitals Bath 
NHS Foundation Trust, Bath, 
UK 
Jay 
Suntharalingam  
Robert MacKenzie Ross, Mark Grover, Ali 
Grove, Jill Peel, Ann Coy 
University of South Paris Marc Humbert David Montani, Florent Soubrier, Barbara 
Girerd, Mélanie Eyries 
VU University Medical Center, 
Amsterdam, Netherlands 
Anton Vonk 
Noordegraaf 
Harm Bogaard, Anna Huis in't Veld, Gwen 
Schotte, Ale Struiksma 
Supplemental Table 2.  Specialist pulmonary hypertension centres participating in the study 
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Recruiting cohorts n 
Genomics England 1965 
Specialist Pathology: Evaluating Exomes in 
Diagnostics 
1356 
Primary Immune Disorders 1299 
Bleeding and Platelet Disorders 1004 
Pulmonary Arterial Hypertension 932 
Multiple Primary Malignant Tumours 376 
Hypertrophic Cardiomyopathy 187 
Cerebral Small Vessel Diseases 183 
Steroid Resistant Nephrotic Syndrome 161 
Intrahepatic Cholestasis of Pregnancy 140 
Stem Cell & Myeloid Disorders 132 
Primary Membranoproliferative Glomerulonephritis 128 
Neuropathic Pain Disorder 114 
Leber Hereditary Optic Neuropathy 59 
Control 15 
Ehlers-Danlos Syndromes 15 
Supplemental Table 3.  NIHR BioResource - Rare Diseases Study 
recruiting cohorts and GEL 
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Parameter Response 
ID  
Date of birth  
Unenhanced CT (Y/N) 
CTPA (Y/N) 
HRCT (Y/N) 
Expiratory CT (Y/N) 
Pulmonary artery diameter (cm)  
Aorta diameter (cm)  
Ground glass opacification centrilobular pattern 
DENSITY 
(None / Subtle / Present) 
Ground glass centrilobular pattern EXTENT (0, <5%, 5-25, 25-50, >50) 
Ground glass DISTRIBUTION 
(central (C)/peripheral (P)/zonal 
(Z) or diffuse (D)) 
Non-specific mosaic pattern / GGO  
Neovascularity vessels (Y/N) 
Arterio-venous malformations (Y/N) 
Bronchial arteries (Y/N) 
Largest bronchial artery size  
Interlobular septal thickening (None, Subtle, Present) 
Mediastinal lymphadenopathy (Y/N) 
Emphysema 
(Y/N) and % of parenchyma 
involved 
Fibrosis 
(Y/N) and % of parenchyma 
involved 
Pleural effusion (Y/N) 
Air trapping (Y/N) 
Comments  
Likely diagnosis 
Any suspicion of PVOD or PCH / 
PAH 
Supplemental Table 4.  Proforma used in analysis of CT scans 
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Group n 
PAH patients with BMPR2 variants 21 
PAH patients with biallelic EIF2AK4 
variants 
7 
PVOD patients 14 
PAH patients with heterozygous EIF2AK4 
variants 
4 
PAH patients with no variants in the 
previously reported PAH genes 
21 
Supplemental Table 5.  CT scans of patients with PVOD and 
patients with PAH carrying biallelic EIF2AK4 mutations were 
reassessed by radiologists blinded to the diagnosis.  For 
comparison CT scans of PAH patients with normal 
spirometry (FEV1 > 80 % predicted and FVC > 80 % 
predicted) who either had no mutations in the previously 
reported PAH genes or carried BMPR2 mutations were 
assessed. 
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Supplemental Table 6.  Page 1/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-2 SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.292C>G missense 
variant 
p.L98V 0 1 0.00001656 probably 
damaging 
(0.999) 
deleterious 
(0) 
25.7 Heterozygous 
variant 
BRIDGE 
control 
c.354_355delTG frameshift 
variant 
p.C118Wfs*7 0 2 Not found 
in ExAC 
  35 Heterozygous 
variant 
BRIDGE 
control 
c.745C>T stop gained & 
splice region 
variant 
p.R249* 0 1 0.00007451   39 Heterozygous 
variant 
BRIDGE 
control 
c.746G>A missense 
variant & splice 
region variant 
p.R249Q 0 1 2.48E-05 probably 
damaging 
(0.999) 
deleterious 
(0.02) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.767G>T missense 
variant 
p.C256F 0 1 1.66E-05 possibly 
damaging 
(0.904) 
deleterious 
(0.02) 
28.4 Heterozygous 
variant 
BRIDGE 
control 
c.985G>A missense 
variant 
p.E329K 0 1 Not found 
in ExAC 
probably 
damaging 
(0.981) 
deleterious 
(0.01) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.1153dupG frameshift 
variant 
p.V385Gfs*30 0 1 0.00003308   32 Heterozygous 
variant 
BRIDGE 
control 
c.1190T>A missense 
variant 
p.I397N 0 1 Not found 
in ExAC 
possibly 
damaging 
(0.67) 
deleterious 
(0) 
32 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (MAF < 0.0001) and predicted deleterious (CADD score > 15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 2/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-2 SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.1215C>G stop gained p.Y405* 0 2 Not found in 
ExAC 
  29.4 Heterozygous 
variant 
BRIDGE 
control 
c.1331A>G missense 
variant 
p.Y444C 0 1 Not found in 
ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
28.7 Heterozygous 
variant 
BRIDGE 
control 
c.1345C>T missense 
variant 
p.R449C 0 1 0.00001654 probably 
damaging 
(1) 
deleterious 
(0) 
35 Heterozygous 
variant 
BRIDGE 
control 
c.2249T>A missense 
variant & splice 
region variant 
p.L750Q 0 1 Not found in 
ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
28 Heterozygous 
variant 
BRIDGE 
control 
c.2298delG frameshift 
variant 
p.N767Tfs*24 0 1 Not found in 
ExAC 
  28.3 Heterozygous 
variant 
BRIDGE 
control 
c.2720A>T missense 
variant 
p.Y907F 0 4 1.66E-05 probably 
damaging 
(1) 
deleterious 
(0) 
31 Heterozygous 
variant 
BRIDGE 
control 
c.2828C>T missense 
variant 
p.T943M 0 1 0.00003311 probably 
damaging 
(1) 
deleterious 
(0) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.3104_3106delT
CT 
inframe 
deletion 
p.F1035del 0 1 Not found in 
ExAC 
  22 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 3/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.3217C>T missense 
variant 
p.R1073C 0 1 0.0000166 probably 
damaging 
(1) 
deleterious 
(0) 
35 Heterozygous 
variant 
BRIDGE 
control 
c.3223T>G missense 
variant 
p.F1075V 0 1 0.0000083 probably 
damaging 
(0.997) 
deleterious 
(0) 
32 Heterozygous 
variant 
BRIDGE 
control 
c.3344C>T missense 
variant 
p.P1115L 0 1 8.26E-06 probably 
damaging 
(1) 
deleterious 
(0) 
35 Heterozygous 
variant 
BRIDGE 
control 
c.3358-3C>T splice region 
variant & 
intron variant 
p.NA 0 1 Not found 
in ExAC 
  17.15 Heterozygous 
variant 
BRIDGE 
control 
c.3406C>T stop gained & 
splice region 
variant 
p.R1136* 0 1 Not found 
in ExAC 
  40 Heterozygous 
variant 
BRIDGE 
control 
c.3430A>T missense 
variant 
p.R1144W 0 1 0.0000248 probably 
damaging 
(1) 
deleterious 
(0) 
33 Heterozygous 
variant 
BRIDGE 
control 
c.3986T>C missense 
variant 
p.F1329S 0 1 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
33 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 4/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
BRIDGE 
control 
c.3992T>C missense 
variant 
p.F1331S 0 1 8.28E-06 possibly 
damaging 
(0.872) 
deleterious 
(0.01) 
28.4 Heterozygous 
variant 
BRIDGE 
control 
c.4039G>A missense 
variant 
p.A1347T 0 1 8.28E-05 probably 
damaging 
(1) 
deleterious 
(0) 
34 Heterozygous 
variant 
BRIDGE 
control 
c.4388_4389+12
delAGGTAAAGAC
GTCA 
splice donor 
variant & 
coding 
sequence 
variant & 
intron variant 
p.NA 0 1 Not found 
in ExAC 
  36 Heterozygous 
variant 
BRIDGE 
control 
c.4397C>A missense 
variant 
p.S1466Y 0 2 Not found 
in ExAC 
probably 
damaging 
(0.988) 
deleterious 
(0) 
33 Heterozygous 
variant 
BRIDGE 
control 
c.4729G>A missense 
variant & splice 
region variant 
p.V1577M 0 1 Not found 
in ExAC 
probably 
damaging 
(0.999) 
deleterious 
(0) 
29.6 Heterozygous 
variant 
BRIDGE 
control 
c.4751dupT frameshift 
variant 
p.L1585Ifs*11 0 1 Not found 
in ExAC 
  34 Heterozygous 
variant 
BRIDGE 
control 
c.4920_4931delT
AGAGATGACTA 
inframe 
deletion 
p.R1641_Y1644
del 
0 1 Not found 
in ExAC 
  23 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 5/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.44C>T missense 
variant 
p.P15L 1 0 8.32E-06 unknown 
(0) 
deleterious 
low 
confidence 
(0.03) 
23.5 Heterozygous 
variant 
PAH c.220G>A missense 
variant 
p.D74N 1 0 1.66E-05 possibly 
damaging 
(0.954) 
deleterious 
(0) 
32 Heterozygous 
variant 
PAH c.1072_1073dup
GT 
frameshift 
variant 
p.V359* 1 0 Not found 
in ExAC 
  32 Heterozygous 
variant 
PAH c.1660G>T missense 
variant & splice 
region variant 
p.D554Y 1 0 Not found 
in ExAC 
probably 
damaging 
(0.966) 
deleterious 
(0) 
28 Heterozygous 
variant 
PAH c.2446C>T stop gained p.Q816* 1 0 Not found 
in ExAC 
  41 Heterozygous 
variant 
PAH c.2516T>C missense 
variant 
p.I839T 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
28.9 Heterozygous 
variant 
PAH c.3218G>T missense 
variant 
p.R1073L 1 0 Not found 
in ExAC 
probably 
damaging 
(0.995) 
deleterious 
(0.01) 
35 Heterozygous 
variant 
PAH c.3604C>T missense 
variant 
p.H1202Y 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
29.7 Heterozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
 
 14 
Supplemental Table 6.  Page 6/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.3711_3713del
GAG 
inframe 
deletion 
p.R1238del 1 0 0.0000083   21.6 Heterozygous 
variant 
PAH c.3722A>G missense 
variant 
p.E1241G 1 0 Not found 
in ExAC 
probably 
damaging 
(0.971) 
deleterious 
(0) 
27.2 Heterozygous 
variant 
PAH c.4646G>A missense 
variant 
p.R1549H 1 0 0.0000910 probably 
damaging 
(0.998) 
deleterious 
(0.01) 
35 Heterozygous 
variant 
PAH c.145-2A>G splice acceptor 
variant 
p.NA 1 0 Not found 
in ExAC 
  23.9 Additional 
second (likely 
trans) variant 
identified 
PAH c.257+4A>C splice region 
variant & 
intron variant 
p.NA 1 0 8.28E-06   15.5 Additional 
second (likely 
trans) variant 
identified 
PAH c.1392delT frameshift 
variant 
p.R465Vfs*38 1 0 2.48E-05   35 Additional 
second (likely 
trans) variant 
identified 
PAH c.1739dupA frameshift 
variant 
p.R581Efs*9 1 0 Not found 
in ExAC 
  35 Additional 
second (likely 
trans) variant 
identified 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 7/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.1820T>G missense 
variant & splice 
region variant 
p.V607G 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
27.3 Additional 
second (likely 
trans) variant 
identified 
PAH c.2727C>G missense 
variant 
p.S909R 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
33 Additional 
second (likely 
trans) variant 
identified 
PAH c.2827A>G missense 
variant 
p.T943A 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
26.4 Additional 
second (likely 
trans) variant 
identified 
PAH c.2841delG frameshift 
variant 
p.I948Sfs*35 1 0 Not found 
in ExAC 
  35 Additional 
second (likely 
trans) variant 
identified 
PAH c.3055_3064delC
TGACCAACG 
frameshift 
variant 
p.L1019Wfs*9 1 0 Not found 
in ExAC 
  36 Additional 
second (likely 
trans) variant 
identified 
PAH c.3097C>T stop gained p.Q1033* 3 0 8.24E-06   45 Additional 
second (likely 
trans) variant 
identified 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 8/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.3325G>A missense 
variant 
p.G1109R 1 0 0.0000082 probably 
damaging 
(1) 
deleterious 
(0.02) 
35 Additional 
second (likely 
trans) variant 
identified 
PAH c.3884T>G missense 
variant 
p.L1295R 1 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
32 Additional 
second (likely 
trans) variant 
identified 
PAH c.4400dupT frameshift 
variant 
p.E1468Rfs*14 1 0 Not found 
in ExAC 
  36 Additional 
second (likely 
trans) variant 
identified 
PAH c.4418_4421delC
AGA 
frameshift 
variant 
p.T1473Rfs*17 1 0 0.0000083   36 Additional 
second (likely 
trans) variant 
identified 
PAH c.4769delT frameshift 
variant 
p.L1590* 1 0 0.0000083   33 Additional 
second (likely 
trans) variant 
identified 
PAH c.281dupA frameshift 
variant 
p.N94Lfs*8 2 0 Not found 
in ExAC 
  35 Homozygous 
variant 
PAH c.1159_1160delC
T 
frameshift 
variant 
p.L387Cfs*27 2 0 Not found 
in ExAC 
  29.6 Homozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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Supplemental Table 6.  Page 9/9 
Project HGVSc Consequence HGVSp Allele 
count 
PAH 
patients 
Allele 
count 
non-PAH 
BRIDGE 
controls 
ExAC MAF PolyPhen-
2 
SIFT CADD 
Phred 
Score 
EIF2AK4 
genotype 
PAH c.1795G>C missense 
variant 
p.G599R 4 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
32 Homozygous 
variant 
PAH c.3097C>T stop gained p.Q1033* 3 0 8.24E-06   45 Homozygous 
variant 
PAH c.3605A>T missense 
variant 
p.H1202L 2 0 Not found 
in ExAC 
probably 
damaging 
(1) 
deleterious 
(0) 
31 Homozygous 
variant 
PAH c.4392dupT frameshift 
variant & splice 
region variant 
p.K1465* 2 0 Not found 
in ExAC 
  35 Homozygous 
variant 
Supplemental Table 6.  Summary of rare (ExAC MAF <0.0001) and predicted deleterious (CADD score >15 and not benign by both PolyPhen-2 and SIFT) EIF2AK4 
variants in NIHR BRIDGE Study.  Transcript: ENST00000263791.5.  EIF2AK4 variants are not shared between PAH patients and controls.  Biallelic EIF2AK4 variants 
are seen only in PAH cases.   
Bold - variants identified in more than one patient in the PAH Cohort.  MAF - minor allele frequency 
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23 M British 
c.3884T>G 
missense 
variant 
C Het   52 3.3 3 97 119 33 Yes 
Possible 
PVOD / 
PCH 
 
PDE5i + 
ERA + IV 
Prostanoid 
No  
c.3055_30
64delCTGA
CCAACG 
frameshift 
variant 
48 M Other 
c.4400dup
T 
frameshift 
variant 
C Het   46 6.4 3 116 120 45 No 
CT not 
available 
for 
analysis 
 
ERA + 
PDE5i + 
inhaled 
Prostanoid 
No  
c.1739dup
A 
frameshift 
variant 
38 F 
Other 
Asian 
c.2827A>G 
missense 
variant 
C Het    40 4.5 2    No 
CT not 
available 
for 
analysis 
 
ERA + 
PDE5i 
No  
c.4418_44
21delCAGA 
frameshift 
variant 
c.145-
2A>G 
splice 
acceptor 
variant 
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown  
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70 F British 
c.1392del
T 
frameshift 
variant 
C Het   76 6.6 3 101 127 33 Unk 
Possible 
PVOD / 
PCH 
 
PDE5i + 
ERA + 
inhaled 
Prostanoid 
No  
c.257+4A
>C 
splice 
region 
variant & 
intron 
variant 
36 F Indian 
c.3605A>
T 
missense 
variant 
Hom    44 2.7 3 73 83 40 Yes 
Possible 
PVOD / 
PCH 
 
ERA + 
PDE5i + 
inhaled 
Prostanoid 
No  
22 M Pakistani 
c.1795G>
C 
missense 
variant 
Hom   65 3.0 3 92 93 31 Yes PAH  
ERA + 
PDE5i + IV 
Prostanoid 
No Yes 
29 M Pakistani 
c.3097C>
T 
stop 
gained 
Hom   50 4.9 3 99 107 27 Unk PAH 
Sister 
died 
from 
PAH 
PDE5i No  
18 M 
Not 
stated 
c.1159_1
160delCT 
frameshift 
variant 
Hom   92  3 86 82 28 No 
Possible 
PVOD / 
PCH 
 
ERA + IV 
Prostanoid 
No  
25 F Pakistani 
c.1795G>
C 
missense 
variant 
Hom   57 5.6 3 82 87 33 No PAH  
PDE5i + 
ERA 
No  
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown  
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24 F 
Not 
stated 
c.2446C>
T 
stop 
gained 
Het 
(both 
on 
same 
allele) 
* 
  60 5.2 3 96 97 81 Unk 
CT not 
available 
for 
analysis 
Father 
and 
sister 
died of 
PAH 
Unk Unk  
c.3218G>
T 
missense 
variant 
39 F British 
c.1072_1
073dupG
T 
frameshift 
variant 
Het   54 3.0 2 87 98 72 No 
CT not 
available 
for 
analysis 
 ERA No  
40 F British c.44C>T 
missense 
variant 
Het  
c.4303-
50delT 
43 5.6 2 99 96 109 Unk 
Possible 
PVOD / 
PCH 
 ERA No  
44 M British 
c.2516T>
C 
missense 
variant 
Het 
c.853-
2A>G 
(splice 
acceptor 
variant) 
c.361-
180A>G 
53 3.8 3 102 98 54 Unk PAH  
PDE5i + 
ERA 
No  
25 F British 
c.3722A>
G 
missense 
variant 
Het     3 53 49 41 No 
CT not 
available 
for 
analysis 
 
PDE5i + 
ERA + IV 
Prostanoid 
No  
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown, *maternally inherited  
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66 F 
Not 
stated 
c.4646G>
A 
missense 
variant 
Het   44 2.1 3 79 100  Unk PAH  
PDE5i + 
ERA 
No  
72 M British 
c.1660G>
T 
missense 
variant & 
splice 
region 
variant 
Het   30 2.8 3    No PAH  
IV 
Prostanoid 
No   
59 F Other 
c.3711_3
713delGA
G 
inframe 
deletion 
Het   41 3.4 3 68 68 95 Unk PAH  
 ERA + 
PDE5i 
No  
48 F British 
c.3604C>
T 
missense 
variant 
Het 
c.2695C>T 
(stop 
gained) 
 57 4.4 4 90 100 61 Unk PAH  
 PDE5i + 
ERA 
No  
70 F 
Other 
White 
c.220G>A 
missense 
variant 
Het   42 5.4 2    Unk 
CT not 
available 
for 
analysis 
 ERA Unk  
Supplemental Table 7.  Phenotypic and genotypic description of patients with a clinical diagnosis of PAH with EIF2AK4 variants. mPAP –  mean pulmonary artery pressure, FC – functional 
class, FEV1 –  forced expiratory volume in 1s, FVC - forced vital capacity, KCO – transfer coefficient for carbon monoxide, PDE5i – phosphodiesterase type 5 inhibitor, ERA –  endothelin 
receptor antagonist, C Het – compound heterozygous, Hom – homozygous, Het – heterozygous, Unk – unknown  
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Supplemental Table 8.  Page 1/2 
 
PAH patients 
with BMPR2 
mutations * 
PAH patients with no 
mutations in PAH 
associated genes 
PAH patients with 
EIF2AK4 heterozygous 
variants 
PAH patients with 
biallelic EIF2AK4 
mutations 
PVOD/PCH 
patients 
p 
n 64 255 3 7 5  
Age (years) 42 [31 - 52] 53 [39 - 67] 39 [32 - 40] 25 [23 - 38] 63 [27 - 76] <0.001 
Gender (n female [%]) 45 [70.3%] 179 [70.2%] 3 [100%] 2 [28.6%] 4 [80%] 0.161 
Ethnicity (n white Caucasian 
[%]) 
50 [78.1%] 226 [88.6%] 2 [66.7%] 2 [28.6%] 4 [80%] <0.001 
Digital clubbing (n [%]) 5 [13.2%] 3 [2.2%] 0 [0%] 2 [40%] 0 [0%] 0.004 
BMI 28 [25 - 33] 27 [24 - 31] 24 [24 - 25] 24 [21 - 27] 27 [24 - 32] 0.202 
Supplemental Table 8.  Phenotype summary of patients with preserved spirometry (FEV1 > 80 % predicted and FVC > 80 % predicted).  PAH patients with 
biallelic EIF2AK4 mutations are still younger at diagnosis and have a significantly reduced KCO compared to other groups. 
mPAP – mean pulmonary artery pressure, CO – cardiac output, PVR – pulmonary vascular resistance, FEV1 – forced expiratory volume in 1 second, FVC – 
forced vital capacity, KCO – transfer coefficient for carbon monoxide, BMI – body mass index.  * Also includes the 2 patients with heterozygous EIF2AK4 
variants and a BMPR2 mutation.  Data presented as median [IQR] unless indicated. Percentages were calculated using the number of patients for whom data 
were available as the denominator. 
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PAH patients 
with BMPR2 
mutations * 
PAH patients with no 
mutations in PAH 
associated genes 
PAH patients with 
EIF2AK4 heterozygous 
variants 
PAH patients with 
biallelic EIF2AK4 
mutations 
PVOD/PCH 
patients 
p 
mPAP (mmHg) 56 (15) 51 (18) 54 (8) 57 (20) 57 (7) 0.008 
CO (L/min) 3 [3 - 4] 4 [3 - 5] 5 [4 - 5] 5 [4 - 6] 3 [3 - 3] <0.001 
PVR (WU) 14 [10 - 18] 10 [7 - 14] 8 [7 - 9] 9 [8 - 15] 14 [11 - 19] <0.001 
Vasoresponders (n [%]) 0 [0%] 18 [21.7%] 0 [0%] 0 [0%]  0.016 
FEV1 (%pred) 97 [88 - 102] 93 [87 - 101] 96 [92 - 97] 97 [89 - 100] 98 [94 - 106] 0.525 
FVC (%pred) 102 [96 - 113] 103 [96 - 112] 97 [96 - 98] 107 [90 - 120] 109 [101 - 113] 0.704 
KCO (%pred) 80 [71 - 93] 68 [46 - 84] 81 [76 - 95] 33 [30 - 33] 33 [28 - 37] <0.001 
Resting SAO2 (%) 96 [94 - 98] 96 [93 - 98] 98 [98 - 99] 91 [90 - 92] 95 [91 - 95] 0.021 
SAO2 post walk test (%) 95 [90 - 98] 91 [85 - 96] 94 [87 - 96] 80 [75 - 84] 85 [85 - 88] <0.001 
Supplemental Table 8.  Phenotype summary of patients with preserved spirometry (FEV1 > 80 % predicted and FVC > 80 % predicted).  PAH patients with 
biallelic EIF2AK4 mutations are still younger at diagnosis and have a significantly reduced KCO compared to other groups. 
mPAP – mean pulmonary artery pressure, CO – cardiac output, PVR – pulmonary vascular resistance, FEV1 – forced expiratory volume in 1 second, FVC – 
forced vital capacity, KCO – transfer coefficient for carbon monoxide, BMI – body mass index.  * Also includes the 2 patients with heterozygous EIF2AK4 
variants and a BMPR2 mutation.  Data presented as median [IQR] unless indicated. Percentages were calculated using the number of patients for whom data 
were available as the denominator. 
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Group  
All biallelic EIF2AK4 
mutation carriers 
PVOD with no EIF2AK4 
mutation 
p 
n  11 10  
Age (years)  26.8 [22.5 - 34.3] 68.3 [63.9 - 72.1] 0.001 
Gender (n female [%])  6 [54.5%] 5 [50.0%] 1.000 
Ethnicity (n white Caucasian 
[%]) 
 5 [45.5%] 9 [90.0%] 0.063 
mPAP (mmHg)  52 [47 - 63] 48 [42 - 57] 0.342 
PCWP (mmHg)  11 [7.5 - 12] 11.5 [9.0 – 12.2] 0.560 
FEV1 (% pred)  93.1 [82.8 - 98.5] 79.0 [72.3 – 91.0] 0.236 
FVC (% pred)  95.5 [84.6 - 108.5] 96.0 [73.0 – 101.0] 0.720 
KCO (% pred)  32.0 [28.7 – 33.0] 41.4 [36.8 – 54.0] 0.013 
Centrilobular ground glass 
opacification density 
None 2 [18.2%] 6 [60.0%] 
0.012 Subtle 2 [18.2%] 3 [30.0%] 
Present 7 [63.6%] 1 [10.0%] 
Supplemental Table 9.  Phenotypic and radiological characteristics of biallelic EIF2AK4 mutation carriers 
compared to patients with a clinical diagnosis of PVOD and no EIF2AK4 mutation. 
 
mPAP – mean pulmonary artery pressure, PCWP – pulmonary capillary wedge pressure, FEV1 – forced expiratory 
volume 1 s, FVC – forced vital capacity, KCO – transfer coefficient for carbon monoxide.  Data presented as 
median [IQR] unless stated. 
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Supplemental Table 9.  Page 2/2 
Group  
All biallelic EIF2AK4 
mutation carriers 
PVOD with no EIF2AK4 
mutation 
p 
Centrilobular ground glass 
opacification extent 
None 2 [18.2%] 7 [70.0%] 
0.007 
<5% 1 [9.1%] 1 [10.0%] 
5-25% 2 [18.2%] 1 [10.0%] 
25-50% 1 [9.1%] 1 [10.0%] 
50-75% 2 [18.2%] 0 [0.0%] 
75-100% 3 [27.3%] 0 [0.0%] 
Interlobular septal thickening 
None 7 [63.6%] 2 [20.0%] 
0.068 Subtle 0 [0.0%] 1 [10.0%] 
Present 4 [36.4%] 7 [70.0%] 
Mediastinal 
lymphadenopathy 
None 4 [36.4%] 2 [20.0%] 
0.635 
Present 7 [63.6%] 8 [80.0%] 
Pleural effusion 
None 11 [100.0%] 6 [60.0%] 
0.035 
Small 0 [0.0%] 4 [40.0%] 
Neovascularity 
None 10 [90.9%] 9 [90.0%] 
1.000 
Present 1 [9.1%] 1 [10.0%] 
CT diagnosis 
PAH 4 [36.4%] 3 [30.0%]  
Possible PVOD/PCH 7 [63.6%] 7 [70.0%]  
Supplemental Table 9.  Phenotypic and radiological characteristics of biallelic EIF2AK4 mutation carriers 
compared to patients with a clinical diagnosis of PVOD and no EIF2AK4 mutation. 
mPAP - mean pulmonary artery pressure, PCWP - pulmonary capillary wedge pressure, FEV1 - forced expiratory 
volume 1 s, FVC - forced vital capacity, KCO - transfer coefficient for carbon monoxide.  Data presented as 
median [IQR] unless stated. 
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Group 
Time to 
assessment 1 
(days) 
n 
Change in 
6mwd (m) 
Change in 
FC 
Time to 
assessment 2 
(days) 
n 
Change in 
6mwd (m) 
Change in 
FC 
Number on 
prostanoid 
therapy 
before the 2nd 
assessment 
[%] 
PAH 
BMPR2 
357  
[314 - 386] 
21 
+69  
[20 - 100] 
-1  
[-1 - -1] 
1120  
[1055 - 1174] 
18 
+45  
[31 - 115] 
-1  
[-1 - -0.5] 
5 [23%] 
PAH 
biallelic 
EIF2AK4 
358  
[335 -388] 
9 
+28 
[-13 - 77] 
0  
[-1 - 0] 
1102 
[1090 – 1112] 
5 
+62  
[-8 - 132] 
0  
[0 - 0] 
1 [10%] 
PAH no 
mutation 
387  
[340 - 414] 
16 
+81  
[61 - 151] 
-1 
 [-1 - 0] 
1118  
[1105 - 1159] 
9 
+104  
[20 - 144] 
-1  
[-1 - 0] 
4 [17%] 
p 0.295  0.343 0.039 0.730  0.748 0.044 0.816 
Supplemental Table 10.  Response to pulmonary artery vasodilator therapies at 1 and 3 years after diagnosis compared to baseline. 6mwd - six-
minute walk test distance, FC - functional class.  Drop in number of patients between assessment 1 and 2 due to death, transplantation or lack of 
sufficient follow up time. Data presented as median [IQR] unless stated. 
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Variable 
Hazard Ratio  
[95% confidence interval] 
p 
PAH BMPR2 mutation* 0.148 [0.055 - 0.396] <0.001 
PAH no mutation* 0.179 [0.073 - 0.440] <0.001 
PVOD* 0.393 [0.075 - 2.065] 0.27 
Age at diagnosis 1.043 [1.033 - 1.053] <0.001 
Male gender 1.631 [1.222 - 2.179] <0.001 
Supplemental Table 11. Cox proportional hazards model assessing time to death.    
Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations had an increased 
risk of death compared to other PAH patients. Number of patients = 858. Events = 194. 
* compared to the PAH biallelic EIF2AK4 mutation carriers 
 
 
Variable 
Hazard Ratio 
[95% confidence interval] 
p 
PAH BMPR2 mutation* 0.175 [0.066 - 0.462] <0.001 
PAH no mutation* 0.203 [0.083 - 0.501] <0.001 
PVOD* 0.840 [0.222 - 3.193] 0.798 
Age at diagnosis 1.036 [1.027 - 1.046] <0.001 
Male gender 1.542 [1.165 - 2.042] 0.002 
Supplemental Table 12.  Cox proportional hazards model assessing time to death or 
transplantation. Number of patients = 858. Events = 208. 
* compared to the PAH biallelic EIF2AK4 mutation carriers 
 
 
Variable 
Hazard Ratio 
[95% confidence interval] 
p 
PAH BMPR2 mutation* 0.376 [0.080 - 1.763] 0.215 
PAH no mutation* 0.456 [0.109 - 1.905] 0.282 
PVOD* 1.029 [0.133 - 7.953] 0.978 
Age at diagnosis 1.034 [1.020 - 1.046] <0.001 
Male gender 1.515 [1.000 - 2.296] 0.051 
Supplemental Table 13.  Sensitivity analysis including only prospectively recruited UK 
patients. Cox proportional hazards model assessing time to death. Number of patients = 
608. Events = 95. 
* compared to the PAH biallelic EIF2AK4 mutation carriers 
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Supplemental Figures 
 
Figure S1 
 
 
 
 
Supplemental Figure Legends: 
Figure S1: Kaplan – Meier survival curves showing survival time (time to death) for patients 
with a clinical diagnosis of PAH or PVOD.  
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